Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

832
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
832
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eutopic echoes ectopic: organoid-based evidence of shared hormone dysregulation in endometriosis.

Reproductive biology and endocrinology : RB&E·2026
Same author

Endometriosis and Fertility: A Practical Guide: Results of the Working Group of the Weissensee 2025 Workshop of the Scientific Endometriosis Foundation.

Geburtshilfe und Frauenheilkunde·2026
Same author

Influence of Structural Features of Peptides on Their Affinity to Cotton Linters Paper.

ACS omega·2026
Same author

Ablation compared with excision in the surgical management of peritoneal endometriosis: a retrospective study of pain, re-operation, and pregnancy outcomes.

Archives of gynecology and obstetrics·2026
Same author

Selective neuronal restoration of progranulin does not prevent the frontotemporal dementia like-phenotype of progranulin knockout mice.

Journal of neuroinflammation·2026
Same author

Endothelial ZBTB16: a molecular shield against cardiac aging.

European heart journal·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
Same journal

A-type potassium channels in pain signaling: Fundamental mechanisms and pathophysiological roles.

Pharmacology & therapeutics·2026
Same journal

GPCR crosstalk beyond obligate dimerisation: Effector coincidence detection, compartmentation, and pharmacological implications.

Pharmacology & therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

"Disease modifying nutricals" for multiple sclerosis.

Katja Schmitz1, Julia Barthelmes1, Leonie Stolz1

  • 1The MS Study Group of the TRIP-Graduate School, Goethe-University Frankfurt, Germany.

Pharmacology & Therapeutics
|December 2, 2014
PubMed
Summary
This summary is machine-generated.

Nutrition and natural compounds show promise for multiple sclerosis (MS) prevention and treatment. Research explores dietary fats, probiotics, vitamins, and plant-based compounds for their disease-modifying effects in MS.

Keywords:
Dietary supplementsExperimental autoimmune encephalomyelitisMultiple sclerosisNutricalsTherapeutics

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.2K

Related Experiment Videos

Last Updated: Apr 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.2K

Area of Science:

  • Neuroimmunology
  • Nutritional Science
  • Pharmacology

Background:

  • The link between vitamin D and multiple sclerosis (MS) has renewed interest in nutritional and natural compounds for managing this neuroinflammatory condition.
  • Various dietary components, including fats, probiotics, vitamins (D, A, E), and phytoestrogens, are being investigated as potential disease-modifying agents in MS.

Purpose of the Study:

  • To review the current understanding of how nutrition and natural compounds may influence the prevention and treatment of multiple sclerosis.
  • To identify novel compounds with anti-inflammatory, immune-modifying, and antioxidative properties for MS management.

Main Methods:

  • Review of studies on experimental autoimmune encephalomyelitis (EAE) models in mice.
  • Exploration of research on dietary factors, gut microbiota, and natural compounds like scorpion toxins, flavonoids, and curcumin.
  • Analysis of potential therapeutic roles of cannabis constituents and endocannabinoid system modulators.

Main Results:

  • Poly-unsaturated fatty acids, beneficial gut microflora, and helminth infections show potential in modulating immune responses and gut-brain communication in MS models.
  • Natural compounds such as epigallocatechin-3-gallate, curcumin, sulforaphane, and scorpion toxins exhibit anti-inflammatory and immune-modulating properties.
  • Cannabis and related compounds may offer complementary benefits for symptom management in MS.

Conclusions:

  • Nutraceuticals and natural compounds show potential to support pharmacological interventions for multiple sclerosis.
  • Further research into these compounds may lead to novel therapeutic strategies for MS, complementing existing treatments.